Pioneering Off the Shelf, Allogeneic T‑Cell Immunotherapies
At Atara, our mission is to transform the lives of patients with serious diseases through pioneering science, teamwork and a commitment to excellence. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases.
Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.
Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need.
Our platform aims to leverage the unique biology of EBV T cells to channel the power of the immune system and has the potential to treat a wide range of diseases.
Atara is applying this one platform to create a robust pipeline with the goal of developing treatments that improve the quality and longevity of patients' lives.
Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need.
Our platform aims to leverage the unique biology of EBV T cells to channel the power of the immune system and has the potential to treat a wide range of diseases.
Atara is applying this one platform to create a robust pipeline with the goal of developing treatments that improve the quality and longevity of patients' lives.
Key Features of Atara’s EBV T-Cell Platform
EBV T cells
EBV T cells naturally possess the following key characteristics:
- Trafficking to the site of the disease
- Specificity for disease targets with a low likelihood to harm normal cells
- Ability to persist in the body long enough to fight disease
Allogeneic Donor Cells
Cells from donors are manufactured and stored in inventory with the goal of being readily available for patients with serious diseases
Next-Generation CAR T Technologies
Next-generation technologies designed to:
- Improve persistence
- Decrease cell exhaustion and death
- Overcome the hostile tumor microenvironment
- Target solid tumors
T-Cell Manufacturing and Delivery Platform
- Robust, scalable manufacturing process
- World-class facility
- Designed for rapid delivery to patients within 3 days
- Biologics-like cost-of-goods profile
Robust Allogeneic T-Cell Immunotherapy Pipeline
Three Strategic Priorities
Tabelecleucel (Tab-cel®) for EBV-driven diseases
ATA188 for progressive forms of multiple sclerosis (MS)
Next-generation CAR T for blood cancers and solid tumors
View Pipeline
“I learned how to cultivate wonder about life’s simple moments because I didn’t know how many moments I had left.”
- Doug
“Don’t give up. That’s the main thing.”
- Ayden
“I have always been very aware of the preciousness of life and that it is something we cannot take for granted.”
- Jessica
“I am who I am because of my disability. People read my story and say, ‘You are a role model to me.’ Hearing that from others is what drives me forward.”
- Ola
World-Class T-Cell Manufacturing
Atara has a dedicated, expandable manufacturing facility with the flexibility to produce multiple T-cell and CAR T immunotherapies. It is designed to meet global regulatory standards and rapidly deliver products to patients from inventory within three days, with commercial validation activities near completion.
Latest News
August 02, 2021
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
View Press Release View All Press ReleasesAugust 02, 2021
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
View Press ReleaseJuly 02, 2021
